Home Featured Page 200

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust)...

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

1...199200201...296 Page 200 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust)...

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY